Daniel Johnson

1.2k total citations
30 papers, 856 citations indexed

About

Daniel Johnson is a scholar working on Oncology, Infectious Diseases and Surgery. According to data from OpenAlex, Daniel Johnson has authored 30 papers receiving a total of 856 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Infectious Diseases and 5 papers in Surgery. Recurrent topics in Daniel Johnson's work include Cancer Immunotherapy and Biomarkers (7 papers), HIV Research and Treatment (5 papers) and Tuberculosis Research and Epidemiology (3 papers). Daniel Johnson is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), HIV Research and Treatment (5 papers) and Tuberculosis Research and Epidemiology (3 papers). Daniel Johnson collaborates with scholars based in United States, United Kingdom and Israel. Daniel Johnson's co-authors include Bo Söderpalm, Mia Ericson, Ola Blomqvist, Jörgen A. Engel, Christopher T. Hanson, Joseph E. Blaney, Stephen S. Whitehead, Brian R. Murphy, Cai-Yen Firestone and David W. Haas and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Daniel Johnson

26 papers receiving 830 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Johnson United States 14 331 228 186 165 152 30 856
Janice A. Williams United States 18 188 0.6× 361 1.6× 237 1.3× 21 0.1× 120 0.8× 28 1.1k
Martin Schaller Germany 11 297 0.9× 93 0.4× 269 1.4× 37 0.2× 102 0.7× 43 750
Yanping Gong China 13 145 0.4× 120 0.5× 257 1.4× 121 0.7× 44 0.3× 24 696
Elisabeth Schuller Austria 20 392 1.2× 167 0.7× 247 1.3× 64 0.4× 58 0.4× 43 1.0k
Andrew K. Hastings United States 21 622 1.9× 186 0.8× 458 2.5× 116 0.7× 140 0.9× 28 1.3k
Christoph Hauser Switzerland 15 86 0.3× 235 1.0× 209 1.1× 96 0.6× 33 0.2× 51 849
Henning Jacobsen Germany 14 162 0.5× 339 1.5× 147 0.8× 97 0.6× 58 0.4× 26 964
Paula Barreras United States 12 326 1.0× 117 0.5× 130 0.7× 70 0.4× 27 0.2× 24 979
Jianchun Xiao China 22 76 0.2× 319 1.4× 520 2.8× 33 0.2× 120 0.8× 61 1.4k
Guillaume Breton France 17 397 1.2× 328 1.4× 560 3.0× 357 2.2× 42 0.3× 53 1.3k

Countries citing papers authored by Daniel Johnson

Since Specialization
Citations

This map shows the geographic impact of Daniel Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Johnson more than expected).

Fields of papers citing papers by Daniel Johnson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Johnson. The network helps show where Daniel Johnson may publish in the future.

Co-authorship network of co-authors of Daniel Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Johnson. A scholar is included among the top collaborators of Daniel Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Johnson. Daniel Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Johnson, Daniel & Mary L. Disis. (2025). Vaccines for cancer interception in familial adenomatous polyposis. Frontiers in Immunology. 16. 1525157–1525157.
2.
3.
He, Aiwu Ruth, Kabir Mody, Kevin Kim, et al.. (2021). A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 39(3_suppl). TPS358–TPS358. 4 indexed citations
4.
5.
Felip, Enriqueta, David R. Spigel, Óscar Juan, et al.. (2021). 140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC. Annals of Oncology. 32. S1438–S1440. 1 indexed citations
6.
Spigel, David R., Delvys Rodríguez‐Abreu, Federico Cappuzzo, et al.. (2021). P77.04 PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors. Journal of Thoracic Oncology. 16(3). S636–S637.
7.
Burton, Jeffrey H., et al.. (2020). Multivariate mortality analyses in COVID‐19: Comparing patients with cancer and patients without cancer in Louisiana. Cancer. 127(2). 266–274. 45 indexed citations
8.
Abudayyeh, Ala, et al.. (2018). The outcome of checkpoint inhibitor therapy in patients with cancer and solid organ transplant: A systematic review of the literature.. Journal of Clinical Oncology. 36(5_suppl). 41–41. 7 indexed citations
9.
Abel, Laurent, Jacques Fellay, David W. Haas, et al.. (2017). Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. The Lancet Infectious Diseases. 18(3). e64–e75. 83 indexed citations
10.
Johnson, Daniel, Thomas Reske, & Marco Ruiz. (2015). Case Report and Review of Immunodeficiency-Associated Burkitt Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 15(6). e121–e125. 3 indexed citations
11.
Schito, Marco, Giovanni Battista Migliori, Helen A. Fletcher, et al.. (2015). Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. Clinical Infectious Diseases. 61(suppl 3). S102–S118. 78 indexed citations
12.
Johnson, Daniel, Charles S. Venuto, Marylyn D. Ritchie, et al.. (2014). Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Pharmacogenetics and Genomics. 24(4). 195–203. 34 indexed citations
13.
Johnson, Daniel, Laura E. Via, Peter Kim, et al.. (2014). Nuclear imaging: A powerful novel approach for tuberculosis. Nuclear Medicine and Biology. 41(10). 777–784. 21 indexed citations
14.
Johnson, Daniel, et al.. (2013). Genetic and Non-Genetic Determinants of Raltegravir Penetration into Cerebrospinal Fluid: A Single Arm Pharmacokinetic Study. PLoS ONE. 8(12). e82672–e82672. 9 indexed citations
15.
Ruiz, Marco, et al.. (2013). Non-AIDS–Defining Cancers in New Orleans. Journal of the International Association of Providers of AIDS Care (JIAPAC). 12(3). 173–177. 3 indexed citations
16.
17.
Blaney, Joseph E., Daniel Johnson, Cai-Yen Firestone, et al.. (2002). Genetic Basis of Attenuation of Dengue Virus Type 4 Small Plaque Mutants with Restricted Replication in Suckling Mice and in SCID Mice Transplanted with Human Liver Cells. Virology. 300(1). 125–139. 88 indexed citations
18.
Hillemanns, Peter, Tedd V. Ellerbrock, Pamela Dole, et al.. (1996). Prevalence of anal human papillomavirus infection and anal cytologic abnormalities in HIV-seropositive women. AIDS. 10(14). 1641–1647. 58 indexed citations
19.
Blomqvist, Ola, Mia Ericson, Daniel Johnson, Jörgen A. Engel, & Bo Söderpalm. (1996). Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment. European Journal of Pharmacology. 314(3). 257–267. 213 indexed citations
20.
Johnson, Daniel, et al.. (1984). Computed Tomography in Medial Maxilla-Orbital Fractures. Journal of Computer Assisted Tomography. 8(3). 416–419. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Janice A. Williams Breakdown of academic impact, for papers by Martin Schaller Breakdown of academic impact, for papers by Yanping Gong Breakdown of academic impact, for papers by Elisabeth Schuller Breakdown of academic impact, for papers by Andrew K. Hastings Breakdown of academic impact, for papers by Christoph Hauser Breakdown of academic impact, for papers by Henning Jacobsen Breakdown of academic impact, for papers by Paula Barreras Breakdown of academic impact, for papers by Jianchun Xiao Breakdown of academic impact, for papers by Guillaume Breton
Rankless by CCL
2026